Collaborative research between academia and industry using a large clinical trial database: A case study in Alzheimer's disease

Trials

Volumn 12, Issue , 2011, Pages

  Jones, Roy ^a   Wilkinson, David ^b   Lopez, Oscar L ^c   Cummings, Jeffrey ^d   Waldemar, Gunhild ^e   Zhang, Richard ^f   Mackell, Joan ^f   Gauthier, Serge ^g  

^a ROYAL UNITED HOSPITAL   (United Kingdom)

^b MOORGREEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Rigshospitalet   (Denmark)

^f PFIZER INC   (United States)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL DATA REPOSITORY; CLINICAL RESEARCH; DATA BASE; DATA MINING; HUMAN; INDUSTRY; LEADERSHIP; ORGANIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); COOPERATION; DRUG INDUSTRY; FACTUAL DATABASE;

ACADEMIES AND INSTITUTES; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COOPERATIVE BEHAVIOR; DATA MINING; DATABASES, FACTUAL; DRUG INDUSTRY; HUMANS; INDANS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 82055169034     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-233     Document Type: Article

References (27)

1. Lee IN, Liao SC, Embrechts M. Data mining techniques applied to medical information. Med Inform Internet Med 2000, 25(2):81-102. 10.1080/14639230050058275, 10901272.
2. Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, Albert K, Schindler R. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord 2009, 23(4):357-364. 10.1097/WAD.0b013e31819cd4be, 19561444.
3. Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings J, Xu Y, Feldman HH. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 28(3):244-251. 10.1159/000241877, 19786776.
4. Gauthier S, Lopez OL, Waldemar G, Jones RW, Cummings J, Zhang R, Schindler R, Schwam E. Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. Int Psychogeriatr 2010, 22(6):973-983. 10.1017/S1041610210000888, 20534179.
5. Cummings J, Jones R, Wilkinson D, Lopez O, Gauthier S, Waldemar G, Zhang R, Xu Y, Sun Y, Richardson S, Mackell J. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis 2010, 21(3):843-851.
6. Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement 2010, 6(6):431-439. 10.1016/j.jalz.2010.04.003, 21044773.
7. Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2011, 26(2):150-157. 10.1002/gps.2507, 20597141.
8. Rogers SL, Friedhoff LT, . the Donepezil Study Group The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996, 7(6):293-303. the Donepezil Study Group.
9. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, . Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998, 50(1):136-145. Donepezil Study Group.
10. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999, 10(3):237-244. 10.1159/000017126, 10325453.
11. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004, 19(7):624-633. 10.1002/gps.1133, 15254918.
12. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, Nishimura T. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000, 11(6):299-313. 10.1159/000017259, 11044775.
13. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 2003, 11(2):169-177.
14. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003, 160(11):2003-2011. 10.1176/appi.ajp.160.11.2003, 14594748.
15. Geldmacher D, Perdomo C, Pratt R. Effect of donepezil treatment on visual attention/exploration tasks in patients with mild to moderately severe Alzheimer's disease: results of a pilot study [abstract]. Neurobiol Aging 2000, 21(1S):S169..
16. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590-1599. 10.1111/j.1532-5415.2001.49266.x, 11843990.
17. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD, . "312" Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology. 2001;57:1942]. Neurology 2001, 57(3):481-488. "312" Study Group.
18. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001, 57(4):613-620.
19. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P, . Donepezil Nordic Study Group A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001, 57(3):489-495. Donepezil Nordic Study Group.
20. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007, 69(5):459-469. 10.1212/01.wnl.0000266627.96040.5a, 17664405.
21. Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomised trial. Dement Geriatr Cogn Disord 2008, 25(5):399-407. 10.1159/000122961, 18391486.
22. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367(9516):1057-1065. 10.1016/S0140-6736(06)68350-5, 16581404.
23. Hoe J, Katona C, Orrell M, Livingston G. Quality of life in dementia: care recipient and caregiver perceptions of quality of life in dementia: the LASER-AD study. Int J Geriatr Psychiatry 2007, 22(10):1031-1036. 10.1002/gps.1786, 17380488.
24. Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 2001, 158(6):872-877. 10.1176/appi.ajp.158.6.872, 11384893.
25. Hogan DB. Donepezil for severe Alzheimer's disease. Lancet 2006, 367(9516):1031-1032. 10.1016/S0140-6736(06)68395-5, 16581383.
26. Wild KV, Kaye JA. The rate of progression of Alzheimer's disease in the later stages: evidence from the Severe Impairment Battery. J Int Neuropsychol Soc 1998, 4(5):512-516.
27. Janus, data standard comparative effectiveness research U S Food and Drug Administration Web site. Accessed August 31, 2011, Janus, data standard comparative effectiveness research., http://www.fda.gov/downloads/AdvisoryCommittees/committeesMeetingMaterials/Scienceboardtothefoodanddrugadministration/UCM224277.pdf